Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase III study of osimertinib as monotherapy or in combination w/chemo vs SOC patients w/NSCLC

A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04351555?term=A+Phase+III%2C+Randomised%2C+Controlled%2C+Multi-centre%2C+3-Arm+Study+of+Neoadjuvant+Osimertinib+as+Monotherapy+or+in+Combination+with+Chemotherapy+versus+Standard+of+Care+Chemotherapy&draw=2&rank=1